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he Congenital
ong QT Syndrome
Mask for Many Faces*
alph Lazzara, MD, FACC
klahoma City, Oklahoma
or most of the latter half of the 20th century, after its
iscovery in 1957 (1), the congenital long QT syndrome
LQTS) was divided simply into 2 forms, the Jervell and
ange-Nielsen syndrome associated with deaf mutism and
he Romano-Ward syndrome with normal hearing. On the
asis of the early reports, both variants were considered
drenergic-sensitive for arrhythmogenesis. This perception
rovided the rationale for the effective therapies of that
eriod—beta adrenergic receptor blockers (2) and left
ardiac sympathectomy (3).
See page 920
In the mid-to-late 1990s, a series of reports in rapid
uccession established that the basic clinical phenotype of
rolonged QT interval and ventricular tachyarrhythmias
ith distinctive morphology (torsades de pointes) could
esult from mutations in 5 different genes encoding subunits
f ion channels that conduct currents critically involved in
epolarization (4–8). Four of the channel subunits form 2
on channels that conduct outward repolarizing lysine po-
assium currents, IKs (KCNQ1 and KCNE1) and IKr
KCNH2 and KCNE2). The other subunit (SCN5A)
ransmits intense inward excitatory current and a low
mplitude depolarizing inward norepinephrine sodium cur-
ent that prolongs the plateau and delays repolarization. The
umerous mutations since described in these genes have in
ommon a prolongation of repolarization by a loss of
unction and reduction of current of the K channels or a
ain of function of the Na channel causing enhanced late Na
urrent. The simple 2-part classification has given way to a
ore complex gene-based classification that includes
QT1-6; JLN 1 and 2; LQT7, the Andersen syndrome (9);
nd LQT8, the Timothy syndrome (10). The LQT4
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
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From the Cardiac Arrhythmia Research Institute (CARI) and Department of
edicine, University of Oklahoma HSC, Oklahoma City, Oklahoma.Ankyrin B), LQT7 (KCNJ2), and LQT8 (CACNA1C)
re more recently discovered genetic variants.
Scientists investigating the links between abnormal func-
ion of the mutant gene products and the clinical manifes-
ations are advantaged by high-precision measurement of
he functions (i.e., the ionic currents) of the normal and
utant ion channels and their components. In addition, the
lectrocardiogram has served as an accessible monitor of the
lobal phenotypic expression of disturbed ventricular repo-
arization. The International LQTS Registry has been an
nvaluable resource of genotyped patients and families
omprehensively studied and followed (11). Information
bout gene defects and their functional and clinical conse-
uences has amplified exponentially.
Amid this abundance of information, a vexatious problem
or the clinician has emerged: the wide variation among
arriers of gene defects in the severity of the prolongation of
epolarization, the response to provocative conditions (trig-
ers), and the arrhythmia risk. The expanded knowledge of
he functional consequences of mutations in the different
enes and the variations in responses of these mutant gene
roducts to pharmacological agents, internal conditions, and
xternal triggers has provided a wider range of gene-specific
herapeutic approaches involving pharmacotherapy and ad-
ustments of life style (12). However, because none of these
pproaches including the standard beta blockade has offered
bsolute protection, implantable cardioverter-defibrillator
mplantation is preferred for those who have failed other
herapeutic measures or are judged to be at high risk (13).
onsequently, risk assessment is a critical component of
he clinician’s evaluation of family members or known
utation carriers.
Variable risk within the whole population of patients with
he congenital long QT syndrome is inevitable. Repolariza-
ion is a complex process governed by the operation of
ultiple ion channels as well as other transport mecha-
isms. Each of the ion channels involved has distinctive
roperties and responses to various conditions. Mutations
n different genes affect repolarization differently depending
n the effect of the defective subunit on the function of the
on channel and the varying conductance of the channel
hroughout repolarization. The nature and severity of the
bnormality of the specific involved current also depends on
he site of the mutation on the gene (14) and, in some cases,
oexistence of certain otherwise clinically insignificant al-
eles (15). The impact on repolarization of a specific genetic
efect and its mutant ion channel is determined not only by
he severity of impairment of the function of the channel
ut by the aggregate of the other processes controlling
epolarization. Repolarization reserve denotes the capacity
f other repolarizing currents to override the negative
ontribution of the mutant channel to repolarization (16).
Tachyarrhythmias associated with prolonged repolariza-
ion depend on triggering by early afterdepolarizations
EAD) that in turn depend on disorders of calcium (Ca)
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March 4, 2008:930–2 Editorial Commentransport induced by prolonged repolarization (17). Adren-
rgic stimulation enhances by multiple mechanisms Ca2
oading of the myocyte, which promotes EAD formation
17). If IKs is intact, Ca
2 loading by adrenergic stimulation
s mitigated by the abbreviation of the action potential
uration by adrenergic IKs enhancement. In the genetic
ariants involving IKs deficiency, provocation of arrhythmias
y adrenergic stimulation is more severe and beta adrenergic
eceptor blockers are more effective. In other variants, the
ole of adrenergic stimulation is not as prominent because
Ks enhancement occurs.
The sustenance of torsades de pointes is likely the result
f macroreentry in a milieu of dispersion of refractoriness
ue to heterogeneity of the distribution of ion channels and
urrents within the ventricular myocardium (18). Variation
mong individuals in the numerous factors involved in these
achyarrhythmia mechanisms adds to the complexity, by
etermining differing susceptibilities to lethal arrhythmias
mong affected individuals.
Against this background of complexity, the identification
f useful risk predictors has been extraordinarily difficult
19). The degree of prolongation of the QTc interval has
merged as the most reliable single predictor of risk for
QT1 and LQT2, but its value in LQT3 is questionable,
nd it is undefined for other more rare forms. Gender
redicts risk variably, depending on the genotype. Risk
aries according to the specific gene involved and the site of
he mutation on the gene. Even a single site mutation
roduces a highly variable phenotype of clinical severity
mong carriers, the phenomenon known as variable pen-
trance (20).
In this issue of the Journal, Schwartz et al. (21) address
ariable penetrance in a large set of South African families
arrying a single mutation on KCNQ1. A previous study by
his group reported that this mutation, KCNQ1-A341V, is
 dominant negative mutation that produces a relatively
evere clinical phenotype (22). The KCNQ1 mutations are
he most sensitive to adrenergic triggers (23), because IKs is
odulated by adrenergic stimulation.
Cognizant of adrenergic sensitivity of arrhythmogenesis
n LQT1, Schwartz et al. (21) investigated sympathetic/
utonomic activity as reflected in heart rate, heart rate
ariability, and baroreceptor sensitivity, and they screened
or adrenergic receptor polymorphisms, attentive to those
hat might affect function. Comparing symptomatic and
symptomatic groups, they found that resting heart rates
ere higher in the symptomatic group, confirming a prior
tudy. Heart rate variability was not significantly different in
he 2 groups. Baroreceptor sensitivity was increased in the
ymptomatic group, a finding ostensibly at variance with
rior studies demonstrating that increased baroreceptor
ensitivity was associated with reduced arrhythmia risk after
yocardial infarction.
The investigators postulate that mutation carriers with
ncreased baroreceptor sensitivity are at greater risk, because
hey are more likely to experience more intense heart rateecelerations and longer diastolic intervals, which are
nown to predispose to EAD triggering. However, barore-
eptor activation produces sympathetic withdrawal, which
ould mitigate the mechanisms for arrhythmogenesis. The
uthors suggest an alternative explanation. Higher barore-
eptor sensitivity might indicate higher sympathetic tone,
he withdrawal of which would cause greater slowing during
aroreceptor activation. Higher heart rates and increased
aroreceptor sensitivity would be linked as indicators of
igher resting sympathetic activity, which plausibly could be
ssociated with greater active sympathetic responses and
reater arrhythmia risk.
They found a relationship between increased barorecep-
or sensitivity and the expression of 2 polymorphisms that
ave been shown to enhance adrenergic activity. The
DRA2C-Del322-325 polymorphism causes reduced
unction of an alpha2 adrenergic receptor, which would
nhance norepinephrine release by reducing inhibitory feed-
ack (24). The ADRB1-G389R polymorphism enhances
oupling of the beta1 adrenergic receptor to adenylyl cyclase
nd augments adrenergic stimulation (25). The finding of a
orrelation between these polymorphisms and baroreceptor
ensitivity is intriguing and supportive of the inference that
he higher baroreceptor sensitivity reflects higher sympathic
one. However, the relationship of these polymorphisms to
esting heart rates or to symptoms has not been determined.
Adrenergic stimulation was the first recognized risk
actor in the congenital long QT syndromes. It is now
ecognized that its role in arrhythmogenesis is most prom-
nent in LQT1, the most common form of the congenital
ong QT syndrome. However, it likely plays a variable role
n other congenital long QT syndromes by affecting Ca
ransport and arrhythmogenesis. Additional studies of the
ctivity of the adrenergic system and its genetic modifiers in
he congenital long QT syndrome, especially LQT1, are
arranted.
eprint requests and correspondence: Dr. Ralph Lazzara, Car-
iac Arrhythmia Research Institute (CARI), 1200 Everett Drive,
E-103, Oklahoma City, Oklahoma 73104. E-mail: ralph-
azzara@ouhsc.edu.
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